Assertio Therapeutics (ASRT) Tops Q2 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Assertio Therapeutics Announces Strong Second-Quarter 2019 Results
August 7, 2019 4:02 PM EDT-- Reports Total Company GAAP Net Sales of $57.2 million, Total Company Non-GAAP Net Sales of $59.3 million, including Commercialization Agreement Revenues of $31.0 million --
-- Drives Continued Improvement in Operating Efficiencies as the Company Executes on its Ongoing Transformation --
-- Confirms 2019 Earnings Guidance Range and Adjusts Neurology Franchise Net Sales Guidance --
-- Continues to Reduce Senior Secured Debt --
LAKE FOREST, Ill., Aug. 07, 2019 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (NASDAQ: ASRT) today reported financial results for the... More
